Search

Roivant Sciences Ltd

Slēgts

SektorsVeselības aprūpe

38.9 6.6

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.42

Max

39.04

Galvenie mērījumi

By Trading Economics

Ienākumi

-646M

-291M

Pārdošana

-1.1M

1.4M

EPS

-0.45

Peļņas marža

-20,152.982

Darbinieki

721

EBITDA

-749M

-294M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+26.03% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.9B

26B

Iepriekšējā atvēršanas cena

32.3

Iepriekšējā slēgšanas cena

38.9

Roivant Sciences Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. nov. 21:03 UTC

Roivant Sciences Ltd is advancing in Friday's session, continuing a trend of gains since Thursday's close, amid unusually high trading volume.

2026. g. 5. nov. 22:02 UTC

Roivant Sciences Ltd is advancing in after-market trading, showing notable strength since Thursday's close and currently positioned well above its 20-day moving average.

2026. g. 4. nov. 21:04 UTC

Roivant Sciences Ltd is sharply higher, exhibiting notable volatility with unusually high market volume, and trading well above its 20-day moving average.

2026. g. 3. nov. 23:16 UTC

Roivant Sciences Ltd's shares are trading modestly higher in after-market hours, recovering from earlier declines while remaining above their 20-day moving average.

2026. g. 2. nov. 20:32 UTC

Roivant Sciences Ltd is declining, reversing a trend of higher daily closes seen recently amid ongoing downward momentum in the market.

2026. g. 30. okt. 19:52 UTC

Roivant Sciences Ltd shares fell as economic data showed a slowdown in business activity, with the Chicago PMI dropping to 55.3 for October.

2026. g. 29. okt. 19:36 UTC

News

Roivant Sciences announces a six-figure legacy donation to the No Patient Left Behind initiative, enhancing drug affordability and access.

2026. g. 28. okt. 23:02 UTC

News

Roivant Sciences shares are declining in after-market trading, despite Citigroup raising its price target to $56 and maintaining a Buy rating.

2026. g. 27. okt. 20:07 UTC

Roivant Sciences Ltd shares advanced, stabilizing near the upper end of its one-month range and remaining above its 20-day moving average.

2026. g. 26. okt. 20:01 UTC

Roivant Sciences Ltd shares are declining, pulling back from an early gain amid broader biotechnology sector weakness, with unusually high trading volume today.

2026. g. 23. okt. 20:07 UTC

Roivant Sciences Ltd shares are declining, reflecting broader market trends, despite retracing slightly after a significant dip earlier in the day.

2026. g. 22. okt. 20:07 UTC

Roivant Sciences Ltd shares rose during Thursday's session, showing unusual strength with an early spike before retracing, and remain significantly above their 20-day moving average.

2026. g. 21. okt. 23:41 UTC

Roivant Sciences Ltd is advancing in after-market trading, having gained since Wednesday's close and currently positioned above its 20-day moving average.

2026. g. 20. okt. 20:08 UTC

Roivant Sciences Ltd is trading modestly higher, closing slightly above Monday's close but remains 1.31% below its 20-day moving average.

2026. g. 19. okt. 20:51 UTC

Roivant Sciences Ltd is trading lower in after-market hours, having pulled back from a brief high earlier in the session and remaining below its 20-day moving average.

2026. g. 16. okt. 22:26 UTC

Roivant Sciences Ltd shares traded higher in after-market hours, maintaining a slight increase from earlier lows amid broader market concerns over inflationary pressures.

2026. g. 15. okt. 19:51 UTC

Social Media

Roivant Sciences Ltd is advancing alongside a broader rise in the Biotechnology sector, as CEO Matt Gline expressed frustration over investor agreements at the #STATSummit.

2026. g. 13. okt. 20:01 UTC

News

Roivant Sciences Ltd shares fell, diverging from recent gains, amid broader market declines, although Citi placed the company on its positive catalyst watch.

2026. g. 12. okt. 23:56 UTC

Roivant Sciences Ltd is trading higher in after-hours action, having previously peaked before a slight retracement, but remains below its 20-day moving average.

2026. g. 9. okt. 19:51 UTC

Roivant Sciences Ltd shares are advancing today, supported by unusually high trading volume, breaking a recent trend of higher daily closes since Thursday.

2026. g. 8. okt. 20:07 UTC

News

Roivant Sciences Ltd shares declined amid negative sentiment from parent company Immunovant following caution from H.C. Wainwright regarding IMVT-1402's mid-stage study.

2026. g. 7. okt. 22:02 UTC

Roivant Sciences Ltd saw a notable rise in after-market trading, gaining ground since Wednesday's close, despite being below its 20-day moving average.

2026. g. 6. okt. 20:07 UTC

Roivant Sciences Ltd shares fell sharply, reaching a midday low and remaining significantly below their 20-day moving average.

2026. g. 5. okt. 23:45 UTC

Roivant Sciences Ltd is trading slightly higher in after-market hours, following earlier gains, despite remaining below its 20-day moving average.

2026. g. 2. okt. 22:02 UTC

Roivant Sciences Ltd is experiencing a significant decline in after-market trading, reaching its lowest point of the day amid unusual volatility.

2026. g. 1. okt. 20:31 UTC

Roivant Sciences Ltd is trading higher in after-market hours, continuing its advance since Thursday's close, despite earlier pulling back from a session high.

2026. g. 30. sept. 21:10 UTC

Roivant Sciences Ltd traded lower in after-market hours, closing at its lowest point of the day and significantly below its 20-day moving average.

2026. g. 29. sept. 22:35 UTC

Roivant Sciences Ltd saw a slight decline in after-market trading, remaining near the lower end of its one-month range and below its 20-day moving average.

2026. g. 28. sept. 22:01 UTC

Roivant Sciences Ltd is rising in after-market trading, advancing from a low point shortly after the market closed, though still below its 20-day moving average.

2026. g. 25. sept. 21:20 UTC

Roivant Sciences Ltd saw a notable increase in after-market trading, recovering from a low point and advancing higher since Friday's close.

Salīdzinājums

Cenas izmaiņa

Roivant Sciences Ltd Prognoze

Cenas mērķis

By TipRanks

26.03% augšup

Prognoze 12 mēnešiem

Vidējais 49 USD  26.03%

Augstākais 62 USD

Zemākais 40 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Roivant Sciences Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

10

Pirkt

2

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat